Artificial Intelligence-Assisted Magnetic Resonance Imaging for Quality, Efficiency and Equity in the National Health Service (NHS) Care of Multiple Sclerosis
AssistMS
2 other identifiers
interventional
1,336
1 country
1
Brief Summary
Multiple Sclerosis (MS) is a long-term disease that affects over 150,000 people in the UK. Starting treatment early is important for managing Multiple Sclerosis (MS). It is also essential to monitor the treatment to see if it is working and to switch treatments if needed. Magnetic resonance imaging (MRI) is the only accepted tool to monitor how well the treatment is working. Current evaluation of brain Magnetic resonance imaging (MRI) scans requires visual inspection, of which sensitivity is degraded by human, and technical factors, such as lack of time, fatigue of radiologists, and lack of standardization of image acquisition protocols across the National Health Service (NHS). MRI-readings can be significantly enhanced by artificial intelligence (AI)-assistive software. Evidence suggests the rate of new lesion detection to be 3 - 4 times higher when using assistive software compared to visual inspection of MRI scans. In this study, an Artificial Intelligence (AI) software called "icobrain ms." developed by the company "icometrix" (Leuven, Belgium) is tested. This tool helps track MS by measuring changes in the brain using MRI scans. The AI can highlight problem areas and create reports that doctors can use to make better decisions about participants' treatment. The aim of the study is to prove that icobrain ms can be used to assist the neuro-radiologist with their visual assessment of MRI scans by a radiologist, and that it will help clinicians make more informed decisions about participants' current MS treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable multiple-sclerosis
Started Jun 2025
Shorter than P25 for not_applicable multiple-sclerosis
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 14, 2025
CompletedFirst Submitted
Initial submission to the registry
August 1, 2025
CompletedFirst Posted
Study publicly available on registry
August 8, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 14, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
April 14, 2026
CompletedAugust 13, 2025
August 1, 2025
10 months
August 1, 2025
August 8, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
To assess the clinical usefulness of icobrain ms by evaluating the detection of disease activity (as defined by new/expanding lesions).
From enrollment to the end of treatment at 12 months
Study Arms (2)
Radiological reading by a neuroradiologist assisted by icobrain ms.
EXPERIMENTALicobrain ms Artificial Intelligence (AI) assistive software
Radiological reading by a neuroradiologist
NO INTERVENTIONStandard of Care
Interventions
icobrain ms is an Artificial Intelligence (AI)-assistive software which quantifies brain Magnetic Resonance Imaging (MRIs) and summarises clinically relevant findings for patients with Multiple Sclerosis in structured electronic radiological reports and annotated images.
Eligibility Criteria
You may qualify if:
- Clinically Isolated Syndrome suggestive of demyelination (CIS) or definitive diagnosis of MS.
- Undergoing MRI head investigation.
- On an MS DMT pathway.
- Access to a smartphone, tablet or computer.
You may not qualify if:
- patients with Multiples Sclerosis participating in a randomised controlled CTIMP (participating in a single arm study may be included, provided this is in line with the other protocol).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Queen Mary University of Londonlead
- icometrixLeuvencollaborator
Study Sites (1)
Barts Health NHS Trust
London, E1 4NS, United Kingdom
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 1, 2025
First Posted
August 8, 2025
Study Start
June 14, 2025
Primary Completion
April 14, 2026
Study Completion
April 14, 2026
Last Updated
August 13, 2025
Record last verified: 2025-08